Honor Medicine (02256) launches buyback program! Chairman Dr. Xu Yaochang simultaneously increases holdings, demonstrating the company's confidence in development and action.

On March 4, 2025, Hony Pharma (02256) announced that the company has repurchased 63,000 shares of the company's stock in the open market, at a price range of HK$6.38 to HK$6.58 per share, with a total cost of approximately HK$410,610. It is worth noting that the day after the board of directors approved the buyback plan, the company promptly initiated the buyback action, demonstrating the management's determination and efficient execution in enhancing shareholder returns. Meanwhile, the company's founder, Chairman, and CEO, Dr. Xu Yaochang, also purchased a total of 45,000 shares of the company's common stock in the open market on March 4, with an average price of about HK$6.48 per share, representing approximately 0.01% of the total issued shares of the company. After this increase, Dr. Xu now holds a total of 79,947,980 shares, representing approximately 11.76% of the total issued shares of the company. Dr. Xu stated that this increase fully reflects his firm confidence in the company's business prospects and future development. Subject to compliance with relevant laws and regulations, Dr. Xu does not rule out the possibility of further increasing his stake in the company in the future. The company's board of directors approved a share buyback plan on March 3, 2025, authorizing the company to utilize up to HK$200 million to repurchase company shares in the open market. The board believes that the current stock price does not fully reflect the company's intrinsic value and growth prospects, and the buyback plan will help enhance shareholder value and strengthen investor confidence.